{
    "clinical_study": {
        "@rank": "80485", 
        "arm_group": [
            {
                "arm_group_label": "Topical anesthetic - L.M.X.4.\u00ae cream", 
                "arm_group_type": "Active Comparator", 
                "description": "Topical anesthetic cream, L.M.X.4.\u00ae cream, applied to one side of the face and neck prior to Ulthera System treatment."
            }, 
            {
                "arm_group_label": "Placebo cream", 
                "arm_group_type": "Placebo Comparator", 
                "description": "A placebo cream with similar consistency and color will be applied to the other side of the face and neck prior to Ulthera System treatment."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the efficacy of a lidocaine topical anesthetic (numbing cream) for\n      reducing discomfort associated with Ultherapy\u2122 treatment."
        }, 
        "brief_title": "Feasibility Study: Evaluate the Effectiveness of Using a Topical Anesthetic Prior to Ultherapy\u2122 Treatment", 
        "completion_date": {
            "#text": "January 2012", 
            "@type": "Actual"
        }, 
        "condition": "Skin Laxity", 
        "condition_browse": {
            "mesh_term": "Cutis Laxa"
        }, 
        "detailed_description": {
            "textblock": "All subjects will receive a full face and neck Ultherapy\u2122  treatment.  Thirty (30) minutes\n      prior to treatment, a topical anesthetic (numbing cream) will be applied to one side of the\n      face and neck and a placebo cream with similar consistency and color will be applied to the\n      other side of the face and neck, in a randomized fashion.  The subject and investigator or\n      sub-investigator performing Ultherapy\u2122 treatment will be blinded to the side to which the\n      topical anesthetic is applied.  Pain scores will be collected following treatment of each\n      section of the face and neck on both sides.  Subjects will return for a 90-day\n      post-treatment visit to assess improvement in skin laxity, and overall lifting and\n      tightening of skin."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, aged 30 to 65 years.\n\n          -  Chosen an Ultherapy\u2122 treatment as part of their treatment regimen.\n\n          -  Subject in good health.\n\n          -  Skin laxity on the face and neck.\n\n          -  Understands and accepts the obligation not to undergo any other procedures in the\n             areas to be treated through the followup period.\n\n          -  Willingness and ability to comply with protocol requirements, including returning for\n             follow-up visits and abstaining from exclusionary procedures for the duration of the\n             study\n\n        Exclusion Criteria:\n\n          -  Known sensitivity to lidocaine or any other anesthetic of the amide type.\n\n          -  History of anaphylactic shock.\n\n          -  Presence of an active systemic or local skin disease that may affect wound healing.\n\n          -  Current therapy with class I antiarrhythmic drugs (e.g., tocainide, mexiletine).\n\n          -  Known or suspected hypersensitivity to LMX-4 active substance, or any of the\n             amide-type local anaesthetics, or any of the excipients (protocol section 10.3).\n\n          -  Severe solar elastosis.\n\n          -  Excessive subcutaneous fat in the face and neck.\n\n          -  Body mass index of 30 or greater.\n\n          -  Excessive skin laxity on the face and neck.\n\n          -  Significant scarring in areas to be treated.\n\n          -  Significant open facial wounds or lesions.\n\n          -  Severe or cystic acne on the face.\n\n          -  Presence of a metal stent or implant in the facial area to be treated."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01708447", 
            "org_study_id": "ULT-117"
        }, 
        "intervention": [
            {
                "arm_group_label": "Topical anesthetic - L.M.X.4.\u00ae cream", 
                "description": "A lidocaine topical anesthetic cream", 
                "intervention_name": "L.M.X.4.\u00ae cream", 
                "intervention_type": "Drug", 
                "other_name": "A lidocaine topical anesthetic cream"
            }, 
            {
                "arm_group_label": "Placebo cream", 
                "description": "Placebo cream containing no anesthetic properties.", 
                "intervention_name": "A placebo cream", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "Topical anesthetic - L.M.X.4.\u00ae cream", 
                    "Placebo cream"
                ], 
                "description": "Focused ultrasound energy delivered below the surface of the skin", 
                "intervention_name": "Ulthera System Treatment", 
                "intervention_type": "Device", 
                "other_name": [
                    "Ulthera\u00ae System", 
                    "Ultherapy\u2122 Treatment", 
                    "Ulthera, Inc.", 
                    "Ultrasound treatment for skin tightening"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anesthetics", 
                "Lidocaine", 
                "Anesthetics, Local"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 27, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Phoenix", 
                    "country": "United States", 
                    "state": "Arizona", 
                    "zip": "85050"
                }, 
                "name": "North Valley Plastic Surgery"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Feasibility Study: Evaluation of the Efficacy of a Liposome-encapsulated Lidocaine Topical Anesthetic for Reducing Discomfort Associated With Ultherapy\u2122 Treatment", 
        "overall_official": {
            "affiliation": "North Valley Plastic Surgery", 
            "last_name": "Steven Gitt, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The validated 10-point pain NRS scale will be used to measure average pain scores reported by subject immediately after each facial region is treated.", 
            "measure": "Treatment-related pain", 
            "safety_issue": "No", 
            "time_frame": "During treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01708447"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Improvement in overall lifting and tightening of skin as determined by a masked, qualitative assessment of photographs.", 
            "measure": "Improvement in skin laxity.", 
            "safety_issue": "No", 
            "time_frame": "90 days post-treatment"
        }, 
        "source": "Ulthera, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ulthera, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}